I
Isabelle Rouquette
Researcher at University of Toulouse
Publications - 84
Citations - 3887
Isabelle Rouquette is an academic researcher from University of Toulouse. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 27, co-authored 83 publications receiving 3134 citations. Previous affiliations of Isabelle Rouquette include Paul Sabatier University.
Papers
More filters
Journal ArticleDOI
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
Fabrice Barlesi,Julien Mazieres,Jean-Philippe Merlio,Didier Debieuvre,Jean Mosser,Hervé Lena,L'Houcine Ouafik,Benjamin Besse,Isabelle Rouquette,Virginie Westeel,Fabienne Escande,Isabelle Monnet,Antoinette Lemoine,Remi Veillon,Hélène Blons,Clarisse Audigier-Valette,Pierre-Paul Bringuier,R. Lamy,Michèle Beau-Faller,Jean-Louis Pujol,Jean-Christophe Sabourin,Frédérique Penault-Llorca,Marc G. Denis,Sylvie Lantuejoul,Franck Morin,Quân Tran,P. Missy,Alexandra Langlais,Bernard Milleron,Jacques Cadranel,Jean-Charles Soria,Gérard Zalcman +31 more
TL;DR: The frequency of genetic alterations, acceptable turnaround times in obtaining analysis results, and the clinical advantage provided by detection of a genetic alteration suggest that this nationwide molecular profiling of patients with advanced NSCLC provides a clinical benefit.
Journal ArticleDOI
Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
Julien Mazieres,Solange Peters,Benoit Lepage,Alexis B. Cortot,Fabrice Barlesi,Michèle Beau-Faller,Benjamin Besse,Hélène Blons,Audrey Mansuet-Lupo,Thierry Urban,Denis Moro-Sibilot,Eric Dansin,Christos Chouaid,Marie Wislez,Joachim Diebold,Enriqueta Felip,Isabelle Rouquette,Julie Milia,Oliver Gautschi +18 more
TL;DR: This study, the largest to date dedicated to Her2-mutated NSCLC, reinforces the importance of screening for HER2 mutations in lung adenocarcinomas and suggests the potential efficacy of HER2-targeted drugs in this population.
Journal ArticleDOI
Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network
Michèle Beau-Faller,Nathalie Prim,A.-M. Ruppert,Isabelle Nanni-Metellus,Roger Lacave,Ludovic Lacroix,Fabienne Escande,Sarab Lizard,Jean-Luc Prétet,Isabelle Rouquette,P. de Cremoux,Jérôme Solassol,F. De Fraipont,Ivan Bièche,Anne Cayre,E. Favre-Guillevin,Pascale Tomasini,Marie Wislez,Benjamin Besse,Michèle Legrain,Anne-Claire Voegeli,Laurence Baudrin,Franck Morin,Gérard Zalcman,Elisabeth Quoix,Hélène Blons,Jacques Cadranel +26 more
TL;DR: Rare EGfr-mutated NSCLCs are heterogeneous, with resistance of distal exon 20 insertions and better sensitivity of exon 18 or complex mutations to EGFR-TKIs, probably requiring individual assessment.
Journal ArticleDOI
Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer.
Julien Adam,N. Le Stang,Isabelle Rouquette,Aurélie Cazes,Cécile Badoual,H Pinot-Roussel,L Tixier,Claire Danel,Francesca Damiola,Diane Damotte,Frédérique Penault-Llorca,Sylvie Lantuejoul +11 more
TL;DR: A multicenter study comparing PD-L1 standardized assays and laboratory-developed tests (LDTs) in non-small-cell lung cancer (NSCLC) and found 28-8, 22C3 and SP263 assays had close analytical performance for tumor cell staining across seven centers.
Journal ArticleDOI
PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.
Nicolas Guibert,Nicolas Guibert,Myriam Delaunay,Amélie Lusque,Nadia Boubekeur,Isabelle Rouquette,Estelle Clermont,Jean Mourlanette,Sandrine Gouin,Inge Dormoy,Gilles Favre,Julien Mazieres,Anne Pradines +12 more
TL;DR: Assessment of PD-L1 expression in CTCs is feasible and C TCs are more often positive than in tissue, which is associated with bad prognosis in patients treated with PD-1 inhibitors.